arrow
O

Othman Al-Sawaf

University of Cologne
H指数:34
被引数:6,425

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Transition Into Clinical Routine and Survival Outcomes of BCL2-and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry

BCL2和BTK抑制剂的临床常规应用及生存结局:一项基于GCLLSG登记数据的患者数据分析

2026-08-010
OAAI
The Landscape and Evolution of Clonal Hematopoiesis in Chronic Lymphocytic Leukemia

克隆性造血在慢性淋巴细胞白血病中的景观与演变

Blood
IF23.1
2025-12-260
OAAI
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia

Al-Sawaf, O.; Stumpf, J.; Zhang, C.; Simon, F.; Bosch, F.; Feyzi, E.; Ghia, P.; Gregor, M.; Kater, A.P.; Lindström, V.; 等. 固定疗程与持续治疗在慢性淋巴细胞白血病中的应用比较. N. Engl. J. Med. 2025, 393, 24. [Google Scholar] [CrossRef]

2025-12-018
PRE
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL

维奈克拉-obinutuzumab在CLL中,体能和剂量强度对临床结局的影响

Blood
IF23.1
2025-08-290
OAAI
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL

维奈克拉-奥比妥珠单抗在CLL中,体能和剂量强度对临床结局的影响

Blood
IF23.1
2025-08-290
OAAI
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial

MRD指导下的zanubrutinib、venetoclax和obinutuzumab在复发性CLL中的应用:CLL2-BZAG试验的主要终点分析

BLOOD
IF23.1
2025-01-301
PRE
Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial

慢性淋巴细胞白血病患者中接受固定疗程Venetoclax-Obinutuzumab或Chlorambucil-Obinutuzumab治疗时的克隆性造血:来自随机CLL14试验的见解

BLOOD
IF23.1
2024-11-050
PRE
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations
2024-05-170
OAAI
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial
2024-04-050
OAAI
The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma

基于人工智能的模型ANORAK改善肺腺癌的组织病理学分级

2024-01-102
OAAI
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial
2023-12-0914
OAAI
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia (vol 14, 2147, 2023)
2023-10-232
OAAI
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
2023-04-1845
OAAI